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Development of antibiotic resistance is one of the main causes for treatment 
failure in microbial infections like Pseudomonas aeruginosa (P.aeruginosa).  It is an 
important and leading cause of nosocomial infections which can be life threatening in 
immune compromised individuals. This pathogen is the most important cause of 
bacteremia, pneumonia, urinary tract infection (UTI), skin, soft tissue infections 
(SSTI). The alarming rise in the trend associated with the isolation of P. aeruginosa 
strains which are resistant to most of the available therapeutic drugs is attributed to 
various factors like, (i) It’s intrinsically resistant to a broad range of antibiotics,        
(ii) The mechanism to acquire resistance determinants due to over usage of 
antimicrobials. 
  
This more over increases the selection of resistant clones. Higher antibiotics 
like Carbapenems exhibit a diversified antimicrobial activity and thereby used as the 
last choice for treatment in multi drug resistant Pseudomonas infections. This 
extraordinary pathogen often carries the necessary mechanisms to resist the action of 
majority of the available therapeutic drugs
 1-2
 
 
Bacteria can resist the action of antibiotics through several mechanisms like, 
alteration of the target, inactivation of the drug, over activity of efflux
 3
 Out of these, 
bacterial efflux pumps are becoming a major concern because they provide bacteria 
the ability to drive away many of the structurally unrelated antibiotics, even before 
their effect begins to onset .
3-5
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Based on their composition, source of energy, number of their membrane-
spanning regions, the types of substrate which gets exported, these pumps are 
classified into five: Adenosine tri phosphate (ATP) binding cassette super family, 
resistance nodulation cell division (RND), Small multi drug resistance (SMR), Multi 
drug and toxic compound extraction (MATE), Major facilitator super family (MFS) 
6-8
 
 
Drug resistance due to efflux in Gram negative bacteria is much more complex 
because of the complex molecular architecture in the envelope of the cell. 
8
 Efflux 
belonging to the RND family is predominant in clinically important multi drug 
resistant bacteria like Pseudomonas aeruginosa. Mex in Pseudomonas and Acr in 
Escherichia coli are known for their organized tripartite systems which comprises of 
periplasmic membrane adaptor protein, cytoplasmic membrane transporter, and an 
outer-membrane channel protein (OMP). 
7
 
                     
             Efflux pump system is one of the main causes of multi-drug resistance (MDR) 
in P. aeruginosa. Efflux pumps of the RND family are predominant in clinically 
important isolates of Pseudomonas. The Mex group of efflux is of utmost interest due 
to their broader substrate specificity. There are twelve active efflux systems which has 
been identified in this family, four of them (MexEF-OprN, MexCD-OprJ, MexAB-
OprM and MexXY-OprM) have been well known and definitely characterized as 
antibiotic transporters thereby conferring resistance to antibiotics and antiseptics.The 
common substrates for efflux are quinolones, cephalosporins, aminoglycosides, anti-
pseudomonal  penicillins and  carbapenems.
11-13
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Inhibitors of Mex efflux pumps have been described among which 
phenylalanine-arginine β-naphthylamide (PAN) and   Carbonyl Cyanide 3-Chloro 
phenylhydrazone (CCCP) restores antibiotic activity in strains which are resistant by 
efflux pump over expression.
(11,12)
 The new direction for other chemotherapeutics is 
by introducing the use of an efflux pump inhibitor (EPI). Using the EPIs together with 
antibiotics can reduce the pathogenicity of   P.aeruginosa along with its role in 
lowering the minimal inhibitory concentration (MIC) of antibiotics. 
(13)
 
 
In this context, development of a reliable and rapid method for detecting efflux 
pumps among the clinical isolates may positively assist for the selection of appropriate 
antibiotics in a given patient and also for the screening of resistance mechanisms in 
epidemiological surveys. The present study was designed to detect the presence of 
efflux mediated resistance to drugs and the effect of efflux inhibitors (PAN, CCCP) in 
restoring the antibiotic activity in   carbapenem   resistant strains of P.aeruginosa.  
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AIM: 
            To detect efflux mediated drug  resistance in clinical isolates of Pseudomonas 
aeruginosa. 
 
 
OBJECTIVES: 
 To isolate and identify Pseudomonas aeruginosa among the clinical isolates. 
 To do antibiotic sensitivity test by automated minimal inhibitory concentration 
(MIC) method (VITEK 2) and other phenotypic methods. 
 To detect the presence of efflux by phenotypic methods like ethidium bromide 
cart wheel agar and inhibitor based assays. 
 To demonstrate the effect of efflux inhibitors such as phenylalanine arginyl 
beta-naphthylamide (PAβN), carbonyl cyanide m-chloro phenylhydrazone 
(CCCP). 
 Molecular characterization of   one of the efflux systems,  MexEF-OprN.   
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INTRODUCTION TO  Pseudomonas aeruginosa:  
 
The first one to mention this bacterium in literature was Schroeter in  1872, in 
his publication it was called Bacterium aeruginosum. Since that time the name was 
changed several times, until the current name appeared and was validly published. 
14
 
Since the isolation, a lot of different information was gathered on its physiology, 
genetics, ecology and phylogeny 
15-16 
  
 
Pseudomonas is a genus of Gammaproteobacteria, which belongs to the family  
Pseudomonadaceae  containing 191 validly described species and the type species 
being   Pseudomonas aeruginosa. 
17,18
 Although  
 
most of the pseudomonads were 
classified originally in the genus Pseudomonas, it is recently known that each of the 
five rRNA groups represents taxonomically different genetic groups, and as a result 
various genus names have been assigned to various groups. Only the members of Rrna 
group l retain the genus name as Pseudomonas.
 19-20 
 
The Rrna group l is the fluorescent group which includes P.aeruginosa, 
P.fluorescens and P.putida. Pseudomonas aeruginosa can be distinguished from the 
rest of its family members by the characteristic blue green pigmentation, acetamide, 
gelatin liquefaction and growth at 42 degree Celsius. Physiological characteristics of 
the P. aeruginosa are as follows: a gram negative rod, which is aerobic and measures 
about 1.5 to 3.0μm by 0.5 to 0.8μm. 21 Furthermore, it secretes different pigments like 
pyocyanin (blue-green), and pyorubin (red-brown) fluorescein (yellow-green and 
fluorescent).
22-23
 Preliminary identification can be done by its specific odor in vitro 
6 
 
and by the blue-greenish colour of the fluorescent producing colonies.
24
 The optimum 
growth temperature is 37°C; maximum temperature of growth is 42°C.
25
 Usually, the 
organisms are motile due to a single polar flagellum. 
26
 P. aeruginosa is a pervasive 
bacterium which invades a wide range of ecologically different habitats and different 
water sources, soil and vegetable material all over the world.  
   
MICROBIOLOGICAL CHARACTERS:    
     
      P. aeruginosa   can produce almost three types of colonies in culture. Natural 
isolates from water and soil can produce rough, small colonies.
27 
Clinical   samples   
produce smooth colony.  Another type has the fried-egg appearance which is smooth, 
large with edges which are flattened and an elevated surface. 
28
 The other type, which 
was frequently obtained from urinary and respiratory secretions, produced mucoid 
colonies, which was associated with the production of alginate slime. 
29
 The mucoid 
and smooth colonies are presumed to play a significant role in virulence and 
colonization.
30
 Apart from pyocyanin production, some strains also produce 
pyoverdin, which is a soluble fluorescent pigment. While pyocyanin is produced in 
abundance in media which has low-iron content and which functions in association 
with   iron metabolism in the bacteria. 
31 
                      
 
CLINICAL MANIFESTATIONS:     
 
 
In humans, P. aeruginosa is seldom a constituent of the normal microbial flora. 
The colonization range for   some of the specific sites are as follows:  0 to 6.6% in the 
throat, 0 to 2% in skin, 2.6 to 24% in fecal samples.
32
 Colonization rates may exceed 
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upto 50% during hospital stay, especially in patients who had undergone trauma or 
any other causes leading to disruption in mucosal or cutaneous membranes by means 
of any in hospital invasive procedures like tracheotomy, mechanical ventilation, burns 
or surgery.
33
 Patients with an immune compromised status are at a greater risk for 
colonization which eventually leads to disruption in the normal flora. 
33 
 
P. aeruginosa is able to cause a large set of different infections, both acute and 
chronic ranging from neonatal sepsis to burns sepsis and acute and chronic lung 
infections. It plays the role of an opportunistic pathogen in patients with defect in host 
defenses like chronic neutropenia, HIV, hematological cancers, diabetes mellitus. It 
commonly infects the respiratory tract of immunocompromised patients and people 
with cystic fibrosis disease (CF).
34-35
  
   
Infection in humans can be classified as opportunistic and those in healthy 
hosts where the infection is acquired when there is a breach in the immune system 
either locally or systemically. Colonization of the skin can lead to catheter related 
infections, colonization in the gastrointestinal tract can lead to pneumonia and 
aspiration. Splashing of water from a contaminated sink or droplets from colonized 
ET tube can pave way for the dissemination and spread of the organism.
36
  
 
Pseudomonas can cause nosocomial urinary tract infections which can be 
associated with the catheter, instrumentation during any invasive procedure. 
Pseudomonas should be suspected in break-through infections in the urinary tract. In 
elderly this can lead to urosepsis.
36
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Pseudomonas is the leading cause of ventilator associated pneumonia in ICU 
settings. Aspiration of these bacteria to the lower respiratory tract leads to VAP by 
P.aeruginosa. It is common in people with chronic conditions and those who require a 
ventilator support. It can lead to blood stream infections and acute respiratory distress 
syndrome as a complication.
36-37
 
 
Infective endocarditis occurs primarily in patients with intravenous drug use. 
Other predisposing factors like prosthetic valve, malignancy, chronic neutropenia and 
chemotherapy can also cause the above said infections. Meningitis due to 
Pseudomonas is very rare unless there is a penetrating wound or the placement of a 
VP shunt or any other surgical procedure involved.  It can cause ocular infections due 
to contaminated lens solution and eye trauma or any recent surgery as well as 
prolonged use of contact lens.
36-39
 
 
There are three major ear infection caused by Pseudomonas aeruginosa. 
Firstly, perichondritis of the ear is more common after an ear piercing which 
commonly involves the auricle. Secondly, otitis externa can be caused due to a local 
infection of the external ear. It can associate with trauma to the ear canal or frequent 
swimming in   pools with contamination. Thirdly, malignant external otitis which is a 
subset of osteomyelitis can be caused by Pseudomonas. It involves the temporal bone 
and base of the skull. Immuno compromised patients are at higher risk.
36,40
 
 
There are several skin and soft tissue infections caused by Pseudomonas like, 
hot tub folliculitis, puncture wounds or osteomyelitis, infections of the foot and nails 
(green nail syndrome), necrotizing fasciitis, ecthyma gangrenosum and most 
9 
 
importantly burns. Infection in burns patients is due to the colonization of the skin 
being replaced with hospital flora containing Pseudomonas.  The fruity odor is 
observed in wounds heavily colonized with this organism.
36, 42
  
                        
 
In spite of Pseudomonas aeruginosa being widely distributed in nature and its 
association with community-acquired cases, the most complicated infections 
associated with P. aeruginosa are the ones which are hospital acquired. The CDC 
National Nosocomial Infections System conducted a surveillance data which showed 
that Pseudomonas was the 5th most commonly isolated nosocomial pathogen, which 
accounted for nearly 9% of all the nosocomial infections in USA. 
43
  
                   
Pseudomonas was the second common cause of hospital acquired pneumonia 
ranging from 13 to 16%, the third frequent cause of urinary tract infection (UTI) (8 to 
11%), the fourth commonly isolated microbe in infections from the surgical site 
(nearly 8%), and 7th most common pathogen to cause disseminated bloodstream 
infections (3 to 6%). Recent studies show that, Pseudomonas aeruginosa is the second 
most common cause of ventilator (VAP) and health care associated pneumonia 
44
 and 
also one of the leading cause of pneumonia in intensive care units among the pediatric 
age group. 
45 
 
Pseudomonas aeruginosa is even more pathogenic in the patients who are in 
the ICU and are critically ill. The National Nosocomial Infections Surveillance 
System has some data regarding the ICU patients which further added that 
Pseudomonas aeruginosa was attributing to 21% of pneumonia, 3% in bloodstream 
infections, 10% in urinary tract infections and 14% in ENT and ocular  infections in 
10 
 
the United States.
45
 One such study conducted in India, identified Pseudomonas 
aeruginosa as the second commonly isolated pathogen in ICU infections. 
42
 In the 
surveillance study that was conducted it was found that, Pseudomonas aeruginosa   
accounts   for 32% of pneumonia, 18% of UTIs, and 12% of bloodstream infections.
42
  
 
VIRULENCE FACTORS IN  Pseudomonas aeruginosa : 
 
The inherent ability of Pseudomonas aeruginosa to produce overwhelming 
infections is due to its synergistic action of excreted enzymes and virulence factors. 
The extracellular products can cause bloodstream invasion, tissue damage and 
dissemination.
 46
 Some of these extracellular factors include Exotoxin A and 
ExoenzymeS.
46-47
 Immunosuppression and local tissue damage is caused by 
exotoxinA. It causes inactivation of elongation factor 2 and catalyses ADP-
ribosylation leading to protein biosynthesis inhibition and cell death. Bacteria growing 
in burned tissues produce exoenzyme S which is detectable in the blood.
 47
  
 
It is responsible for tissue destruction in lung infection and may also be 
important in the organism’s dissemination. Pseudomonas aeruginosa produces few 
proteases (alkaline protease, LasA and LasB elastase) which are able to destroy the 
protein elastin found in human lung tissue. This therefore interferes with the 
expansion and contraction functions of the lungs. 
47
  
 
P. aeruginosa also has the ability to do cell-to-cell signaling and this enables it 
to monitor the production of its cell density and extracellular virulent factors. The cell-
to-cell singling system is called the Las system, since it regulates the expression of 
11 
 
LasA and B elastase.
48-50 
The las system helps in the production of other virulence 
factors like, LasA protease and exotoxinA.
48,51
 The importance of this cell-to-cell 
signaling  is that through the regulated and coordinated expression of virulence genes 
by the bacterial population as a whole, they tend to secrete extracellular factors only 
when they can be useful, thereby allowing it to fight the hosts defense mechanisms
52-54
 
 
Some mutants of P. aeruginosa produce an exo-polysaccharide called alginate. 
This is a slime matrix that forms biofilm in which its micro colony mutants grow. The 
biofilm protects the organism from the actions of antibiotics and disinfectants and 
hence allows the bacteria to survive under harsh conditions. 
54 
 
SUSCEPTIBILITY IN VITRO AND IN VIVO: 
 
Antimicrobial agents are needed to treat Pseudomonas infections are needed to 
be treated with antimicrobials. A combination therapy which consists of two 
antipseudomonal drugs like, a beta-lactam antibiotic with an aminoglycoside which is 
usually prescribed for the initial empiric treatment, especially in cases of sepsis, 
bacteremia, abscess formation and  upper respiratory infections (URIs). Carbapenems 
like Meropenem and imipenem along with antipseudomonal quinolones can be used 
along with an aminoglycoside. Except in of cases of febrile neutropenia where a 
monotherapy with ceftazidime or a carbapenem  is use. The antibiotic of choice also 
depends on the extent and site of infection and local resistance patterns.
55-59
 
 
Infections caused by Pseudomonas are becoming increasingly resistant to many 
of the antibiotics, and it may also acquire resistance during therapy.   Proving to be 
12 
 
one of the   leading  cause of nosocomial infections, P.aeruginosa is of more threat 
due to the increase in antimicrobial resistance.  It utilizes different mechanisms to 
exhibit resistance. While the evidence of such mechanisms alone does not justify   
resistance.
60
   On a detailed study it was found that resistance was established due to a 
single factor or a combination of several mechanisms like, alteration of the target, 
inactivation of the drug, over activity of efflux
. 
Pseudomonas produces a variety of 
beta lactamases like extended spectrum beta lactamases (ESBL), chromosomal 
cephalosporinase (AmpC) and metallo beta lactamases (MBL). 
61
                                    
 
Pseudomonas aeruginosa isolates from patients in ICU shows higher rates of 
β-lactam resistance than general trends for hospitalised patients. In a study conducted 
by Appalaraju et al. in our own center, reported 22% of the clinical isolates of 
Pseudomonas were multidrug resistant and 4% were pan drug resistant ones, with 
15.5% being ESBL producers and 54.5% were MBL producers. 
62 
 
Inherent resistance to many antibiotics along with other acquired mechanisms 
makes it more problematic in the antibiotic era. Pseudomonas aeruginosa exhibits the 
highest rate of resistance for fluoroquinolones, with resistance to levofloxacin and 
ciprofloxacin ranging from about 20 to 35%. 
63
 Among aminoglycosides, studies 
focused mostly on gentamicin, with a resistant rate ranging from 12 to 22% with 
lower rates of   resistance   for   amikacin and tobramycin.  Not surprisingly, the 
highest rates of resistance were reported for isolates obtained from patients in ICUs. 
63
                       
 
Studies have found out that MBL producing   Pseudomonas are commonly 
associated with blood stream infections and with a higher mortality and morbidity. 
13 
 
The ampC gene is present in almost all strains of Pseudomonas but only when there is 
a mutation it can lead to increased production and exhibiting resistance.
63 
The 
commonly used drugs for treating Pseudomonas infections are carbapenems. They are 
proven effective against beta lactam producing strains.  Increase in prevalence of 
carbapenems resistance is observed worldwide. 
63
 a study in UK showed that 
prevalence of carbapenem  resistance  over the past five years in a tertiary care 
hospital showed a rise in trend from 53% to 88%. In addition mutations in OprD can 
inhibit the entry of imipenem into the bacterial cell. 
64-66
 
                           
Even though the national surveillance studies provide significant data   in the 
trends of resistance for consideration, they have not stressed on the potential of this 
pathogen for causing higher resistance rates in hospitals as well was communities. For 
instance, from 2001 to 2006, the rates of non susceptibility in isolates of 
P.aeruginosa , varied from 30 to 31% for imipenem, 27 to 29% for cefepime, 41 to 
44% for ciprofloxacin and 23% for meropenem. 
43
 The rates are surprisingly greater 
than those among the national trends which does the focusing on the hospital isolates 
of   Pseudomonas  aeruginosa.
 67-69 
 
Not only does the resistance rates to individual or a class of drug, but also the 
prevalence of multi drug-resistant (MDR) isolates is an even more serious  challenge 
in therapeutics. The MDR isolates of   P. aeruginosa reported by Flamm et al. was 
ranging from 40 - 50% 
54 
and in India by Appalaraju et al., reported that 22% of the 
clinical isolates of Pseudomonas were multidrug resistant and 4% were pan drug 
resistant. The isolated MDR strains was found to be more prevalent in isolates 
14 
 
obtained from lower respiratory tract infections and isolates from upper respiratory 
tract infections had the lowest prevalence. 
69
 It’s not surprising to see that, MDR 
strains were frequently isolated from nursing home and ICU patients. 
  
RESISTANCE CHALLENGES IN THE TREATMENT OF   P.aeruginosa 
 
What actually makes Pseudomonas aeruginosa significantly problematic is a 
combination of the   following: (i) It has inherent   resistance   to many classes of   
drugs, (ii) It has the potential to acquire resistance due to mutations and all relevant 
treatments, (iii) It has increasingly higher rates of resistance locally and its significant 
role in causing serious infections.  
 
Although a few isolates of   Pseudomonas  aeruginosa  are found to be 
resistant to most of the available antibiotics, this makes it even more problematic with 
the evolution of integrins which carry the gene cassettes encoding  for  both amikacin 
acetyl transferases and carbapenemases.
 70 
 
Imported Resistance Mechanisms: 
 
In accordance with the available anti-pseudomonal drugs, imported resistance 
in these isolates has impact on the aminoglycosides and β-lactams except for the 
fluoroquinolones. 
70
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Chromosomal Encoded Resistance Mechanisms: 
The most commonly studied chromosomally encoded resistance mechanisms 
are:  
 (i) The OprD outer membrane, (ii) The AmpC cephalosporinase  (iii) The multi drug 
efflux pumps. 
 
 Resistance to β-Lactams and AmpC: 
 
Pseudomonas   carries within itself an AmpC cephalosporinase which is 
inducible and more in similarity to the AmpC which is being chromosomally encoded 
as in other members of Enterobacteriaceae. 
70-72
 Wilder strains of Pseudomonas will 
produce very minimal levels of AmpC and will be susceptible to most of the anti 
pseudomonal penicillins, carbapenems, cephalosporins and penicillin-inhibitor 
combinations. 
72
  
 
Therefore, if there is an excess production of these enzymes 
AmpC, Pseudomonas aeruginosa continues to develop resistance to other β-lactams, 
except carbapenems. However, the AmpC deficient strains of Pseudomonas which 
are evolved through the exchange of alleles, is found to show a four-fold increase in 
susceptibility to panipenem and imipenem except meropenem. 
72 
 
OPR D- MEDIATED RESISTANCE: 
 
In gram negative bacteria there is an outer membrane which acts as a barrier 
and is semi permeable and slows down the antibiotic penetration into the cell. The 
16 
 
outer membrane permeability of Pseudomonas aeruginosa is only eight percent as that 
of E.coli.  
(72)
 For survival, Pseudomonas aeruginosa should allow free passage of 
necessary nutrients into and out of the cell, and it can be done by a collection of   
protein channel, known as porins.
 72
 
 
The sequence analysis of the genome of Pseudomonas has nearly revealed 163 
outer membrane proteins (OMP), with almost 64, being grouped into three different 
porin families. These have a significant role in the transport of sugars, amino acids 
(AA), cations, siderophores, phosphates.
72 
Thereare few antibiotics which are 
hydrophilic like, beta lactams, tetracyclines, aminoglycosides, few fluoroquinolones 
which are known to transverse the membrane of bacteria through the available porin 
channels available. 
(73)
 Hence, when there is a loss of any particular porin channel, it 
will certainly lead to the reduction in the susceptibility of   Pseudomonas   aeruginosa  
 to few antibiotics. 
73 
 
EFFLUX-MEDIATED RESISTANCE: 
 
Antibiotic efflux was  reported  in 1970s in bacteria for the class of antibiotic 
namely,  tetracyclines. However, in mammalian cancer cells drug efflux which was 
mediated by p- glycoprotein, was discovered even more earlier. In case the given drug 
is pumped out more faster than even it can even take it in, the drug concentrations 
inside the bacteria will be   kept very low and ineffective. 
74   
 
Active efflux is one effective mechanism which is responsible for moving 
compounds such as antibiotics, neuro transmitters and toxic products out of the 
17 
 
bacterial cell. It is of prime importance in the xenobiotic metabolism. In relation to 
medicine it is considered very important as it confers to the emergence of drug 
resistance. These are basic mechanisms which requires energy source for functioning. 
Some of these are specific for certain drugs and   few may be associated with   
multiple drugs thereby paving way for multi drug resistance. 
 
BACTERIAL EFFLUX PUMPS: 
These are proteinaceous transporters situated in the cytoplasmic membranes of 
almost all the cells. They require energy source to transport the materials out of the 
cell and hence it is categorized as active transport. Those which utilize ATP as the 
energy source are termed as primary active and those that associate transport with an 
electrochemical gradient are secondary active. 
 
TYPES OF EFFLUX: 
Phylogenetically, bacterial antibiotic efflux pumps is classified into five super 
families like, (1) Small multi drug resistance (SMR) (2) Multi drug and toxic 
compound extraction (MATE) (3) ATP-binding cassette (ABC) (4) Major facilitator  
super family (MFS) (5) Resistance nodulation cell division (RND) Of these only the 
ABC family utilizes ATP, whereas the rest uses electrochemical gradient.
74
 
 
These pumps are nothing but a variant of the membrane pump which all the 
bacteria has within it,  in order to remove the amphipathic and lipophilic molecules 
out of the cell. In case of any disruption in the genes for multi drug efflux pumps 
might result in an immense decrease in resistance against multiple antibacterial    
agents. 
74
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This is one of the   resistance   mechanisms in Gram negative bacteria. Efflux 
systems which are clinically relevant in gram negative bacilli, belong to the RND 
family which is made of a cytoplasmic membrane pump, an outer membrane protein 
and a Membrane Fusion Protein. 
75
 
 
STRUCTURE OF EFFLUX PUMPS: 
 
There are almost twelve transmembrane helices (TMH), and two six-helix 
bundles which are formed by the N and C terminal domains which are homologous 
and
 
connected by an   extended   cytoplasmic loop. They are arranged in a clam-shell 
fashion which subsequently forms a large aqueous filled cavity at   the center. It acts 
similar to “Rocker-switch" mechanism. 
 
Figure 1:  The arrangement and mechanism of efflux 
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Efflux of the antibiotic: 
For any of the given antibiotic to be effective it must first of all reach its 
specific target within the cell and try to accumulate at its maximum concentration in 
order to act within a reasonable time frame. Like antibiotics which acts on the 
ribosome should necessarily pass along the cell membrane and make way into the 
cytoplasm for further accumulation at very high concentrations to block the specific 
step in the assembly of proteins 
76
 
For both eukaryotic and bacterial cell  contain a huge pack of  membrane  
transport  systems which are highly participating in vital roles like, intake of particular 
nutrients, maintaining  cellular homeostasis and excretion of toxic compounds. 
76
 The 
increase in numbers of the transport systems identified, are due to exploding use of 
sequencing and cloning  over the recent past.
77
As of now, 300 gene products are 
known to transport substrates, and out of which 20-30 transport only antibiotics. 
77
     
Gram positive and negative bacteria produces proteins, which can at times it 
can act as efflux pumps for certain antimicrobials in general. In case the antibiotic is 
being pumped out fast than it gets in, the ultimate end concentrations are going to be 
kept low. These efflux pumps are variants of membrane pumps that bacteria has 
within it to move amphipathic and lipophilic molecules out of the cell.  Some 
microbes capable of producing antibiotics, possess the pump to throw out the 
antibiotics as quick as they are produced. This serves as a mechanism which protects 
the microbe and prevents it from being destroyed by its own weapon 
(77)
  
 
20 
 
 
Many of these efflux pumps are found to have broad substrate specificity and, 
can even deal with a wider range of drugs which are of a completely unrelated 
pharmacological class. Efflux of the drug eventually decreases the burden on 
detoxification which is mediated by efflux, by avoiding the saturation, whereas the 
modification based on enzyme systems, tends to increase the amphiphilicity of the 
drug and provides it with even better substrates 
78
 
                     Table 1: ORGANISMS AND THE ASSOCIATED EFFLUX 
Microorganism 
Efflux Component 
MFP RND 
E.coli AcrA AcrB 
AcrE AcrF 
H.influenzae AcrA AcrB 
N.gonorrhoea MtrC MtrD 
P.aeruginosa MexA MexB 
MexC MexD 
Salmonella typhimurium AcrA AcrB 
S.maltophila SmeA SmeB 
E.aerogenes AcrA AcrB 
Acinetobacter AdeA AdeB 
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Four of the protein families that belong to efflux and can function in antibiotic 
resistance are mentioned above and studied in detail. Most of the efflux works by 
coupling efflux to a counter flow of protons, and ABC family enhances the hydrolysis 
of ATP to provide sufficient energy for actively transporting the antibiotic inside and 
outer of the cell. 
79
  
 
Those which use proton motive force as an energy source are classified into 
small multi drug regulator (SMR), major facilitator subfamily (MFS), RND, based on 
its size and the need for proteins and its corresponding units. The proton driven anti-
porters are more dominant in bacterial genomes whereas the ATP-driven ones are 
dominant in the eukaryotes. 
79
 
 
Those genes which are encoding for the efflux pumps are found on 
transposons, plasmids and even as part of integrons, which facilitates the widespread 
dissemination. However, most of the genetic elements   for the   pumps are found to 
be coded in the microbial genomes 
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The substrate recognition mechanism and transport remains unknown, and 
various opinions are based on extrapolations among various data from transport of the 
physiological substrates. MFS, RND and SMR systems use proton gradient as the 
driving force.   
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The net effect of transport system results in an exchange of a drug and a proton 
(antiport). And for proton anti-porters, a change in the confirmation of ABC protein is 
essential for extrusion of the drug and this can get triggered due to the by binding of 
the drug and ATP hydrolysis 
80
. The definite mechanism for the drug transport is still 
controversial.  
 
                
 
Figure 2: An overview of the different efflux systems 
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RND FAMILY: 
This class of efflux contains multi drug efflux transporters found mostly in 
gram negative bacilli. This is basically a system which contains three components, 
which can eventually bypass the periplasm and provide efflux between the inner and 
outer membranes.  Such a system must require:  
(i) an outer membrane channel (ii) a membrane fusion protein (MFP) (iii) an inner 
membrane transporters.
81
 
Figure 3: The components of RND efflux pumps 
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It is assumed that the membrane fusion protein can perform either of the following: 
(a)  Can   form a channel between the outer and inner membranes (b) can act as a 
force to pull both the outer and inner membranes together. (c) Initiate a transfer 
between the membrane translocate. 
The membrane fusion protein and inner membrane transporter are encoded on the 
same operon.  The pumps of this  superfamily includes  
 Mex - exhibiting resistance to beta lactam inhibitors, chloramphenicol, amino 
glycosides and beta lactams.  
AmrB - predominantly shows resistant to erythromycin and amino glycoside. 
 Acr -  for erythromycin, nalidixic acid, tetracycline, chloramphenicol, rifampin and 
beta lactams. 
 MtrD - for fluoroquinolones, chloramphenicol,beta lactams,erythromycin and 
tetracyclines. 
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The efflux pumps are known to play a major role in antimicrobial resistance 
exhibited by Pseudomonas aeruginosa to various drugs like tetracyclines, 
chloramphenicol, beta lactase and fluoroquinolones. Among the various efflux pumps 
available, the Mex family is what predominates in the Pseudomonas. MexAB- OprM 
and MexXY-OprM are found to be associated with both acquired and intrinsic 
resistance, whereas MexEF-OprN and MexCD-OprJ are attributable to acquired 
resistance alone. 
84 
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                    Table 2: The various efflux pumps in Pseudomonas aeruginosa 
  
 
 
In E.coli, the AcrAB-TolC is one of the predominant efflux system. However, 
most of the efflux systems in E.coli share a common outer membrane channel named 
as TolC. In ciprofloxacin resistant cases there is an associated over expression of 
AcrA. 
 
MFS FAMILY: 
 
This is an example of uniporter- symporter- antiproter family. it contains at 
least 18 known families of transporters of which few are responsible for import and 
some are responsible for export whereas the rest are associated with either antiprotons 
or transporters. These include, In E.coli, Tet A, EmrB, Mdf A, Tet K and GmlA types 
of efflux are seen and in Pneumococcus its MefE and MefA. 
85 
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Table 3: the various genes associated with antibiotic resistance 
S.No Genes Resistant Antibiotics 
1 Tet A,B,E   Chloramphenicol, nalidixic acid 
2 Tap   Tetracycline 
3 Tet C Tetracycline 
4 Tet H Tetracycline 
5 CmlA Chloramphenicol 
6 Bcr    Sulphonamide 
7 Nor A Chloramphenicol, fluroquinolone, tetracycline 
8 Blr Chloramphenicol ,fluroquinolone 
9 Emr B Nalidixic acid 
10 MdfA    Tetracycline, aminoglycoside, erythromycin 
11 LftrA    Fluroquinolone 
12 TetK   Tetracycline, Macrolides 
13 Emr    Chloramphenicol, erythromycin, tetracycline 
14 Tet V    Tetracycline 
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SMR FAMILY:  
 
This family is exclusive to only the bacterial cells available.  It is associated 
with the transport of  lipophilic drugs. The mechanism of transport is by site-directed 
mutagenesis, and it consists of these steps: 
(a) There is an exchange between a proton which is on a charged residue and the 
drug;  
(b) Translocation of drug which can happen by change in conformational and 
thereby throwing  it away by hydrophobic pathway;  
(c) A proton replaces the drug in the external  surrounding  thereby  returning it  to 
its initial state. 
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EmrE - found mostly in E.coli and M.tuberculosis 
EmrE - establishes resistance to sulphonamides, erythromycin and tetracycline 
Mmr - is associated with erythromycin resistance. 
 
MATE FAMILY: 
 
The multi antimicrobial extrusion protein functions along with sodium or drug 
symporters or antiporters. This is found in eukaryotes and bacteria where they carry 
out the function of xenobiotic metabolism. It consists of a twelve alpha helical 
membrane structure and an additional C terminal. The multidrug exporter NorM 
isolated from V.parahemolyticus and E.coli was discovered in 1998.This family 
consists of NorM, which exhibits resistance to fluoroquinolone and ahminoglycosides. 
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In E.coli it has four transporters, one in H.influenza and six in Pseudomonas 
aeruginosa. 
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ABC TRANSPORTERS: 
It is one of the largest and probably the oldest system of efflux in bacteria. 
These are primary active transporters which require ATP for functioning properly. It 
consists of multiple subunits which has transmembrane proteins and associated ATP 
ases. They transport drugs, lipids and sterols. There are more than hundreds of ABC 
transporters associated with prokaryotes and eukaryotes. They are of potential role in 
paving way for multi drug resistance in bacteria.  
 
It is not clear about how so many drugs get transported across this protein 
material. One of the proposed hypothesis being, the role of p-glycoprotein in binding 
to various drugs.  These systems contain an ATP binding cassette, but not a 
hydrophilic domain as found in the above systems. Those pumps among the ABC 
groups include LmrA, SrmB, MsrA, TirC, OleC. Those found in E.coli are LsA, with 
resistance to clindamycin and ArsAB associated with resistance to arsenate. 
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EFFLUX INHIBITORS: 
 
There are many trials which are conducted to employ certain drugs which can 
be administered along with antimicrobials so that it can act as inhibitors for throwing 
out antibiotics which are efflux-mediated. As of now, there is no inhibitor specific for 
efflux which has been approved for patient use, while few used to express the 
prevalence of efflux in the clinical isolates and in research. Verapamil, can block the 
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efflux which is mediated by the P-glycoprotein of DNA-binding fluorophores, and 
helping cell sorting for DNA content by fluorescence.  
 
Few of the natural derivative products have shown to exhibit anti-efflux pump 
activity including the carotenoids capsorubin and capsanthin, the alkaloid lyserogol 
and flavonoids chrysin and rotenone. There are many efflux inhibitors like, 
phenylalanine-arginine β-naphthylamide (PAN), Carbonyl Cyanide 3-Chloro 
phenylhydrazone (CCCP) and reserpine but none of them are available for clinical 
use.  Few nano particles like Zinc Oxide is found to be associated in the regulation of 
efflux pumps. 
89
 
 
Figure 4: Mechanism of action of efflux inhibitors 
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The rapid increase in the trend of bacteria expressing resistance to multiple 
drugs has led to the emergence of newer antimicrobials and likewise the resistance 
modifying agents. Ever since the discovery of efflux, people have been trying to 
characterize it   and develop certain mechanisms to overcome these efflux. 
( ) 
Since 
efflux is one of the mechanisms establishing resistance, the need to take over it is very 
essential. So the role of these inhibitors is of prime importance in this era.  
 
SCREENING FOR EPI: 
 
Certain antibiotics are known to exhibit synergy when they are used in 
combination with certain others. This can even be demonstrated by the chequerboard 
assay. Many variations of this method have been employed to detect the potential 
inhibitors of efflux. The Et-Br efflux inhibition assays give more detail on the 
potential activity of any test compound. This Et-Br is a substrate for most of the efflux 
associated with multi drug resistance. The activity of efflux inhibitors can be 
demonstrated by fluorometric assays. 
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COMMONLY USED EPIs: 
(a) Reserpine:   
                  An indole alkaloid, commonly used against hypertension and also an 
antipsychotic drug, is known to inhibit efflux. However, because of its 
numerous side effects it is rarely been used nowadays. 
91
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(b) Phenylalanine-arginine-beta-napthylamide:  
This is again a very well studied inhibitor which is frequently combined 
with antibiotics like fluoroquinolone. Only limited studies are done along with 
beta lactams. Our study has focused on the determination of efficacy of PAN in 
combination with beta lactams against one of the dangerous pathogen 
P.aeruginosa. PAN has reduced the MIC of various beta lactams against 
Pseudomonas. 
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(c) Carbonyl Cyanide 3-Chloro phenylhydrazone (CCCP):   
This is another efflux inhibitor which has action against both the gram 
positive and negative bacteria. 
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Drug efflux is a major contributor to the development of resistance and 
blocking this efflux by any of the possible means can increase the drug concentration 
within the bacterial cell and led to the death of the organism.  The new direction for 
other chemotherapeutics is by introducing the use of an efflux pump inhibitor (EPI). 
Using the EPIs together with antibiotics can reduce the pathogenecity of  
P.aeruginosa along with its role in lowering the minimal inhibitory concentration 
(MIC) of antibiotics. On the other hand the EPI activity can get even more 
complicated by non-efflux related side effects.  
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In India efflux studies conducted by Manju suresh et.al., in North Kerala and 
Choudary et.al., in North India  shows the prevalence of efflux in various organisms 
like Pseudomonas (34.8%), E.coli (19%), Acinetobacter spp (9%) and Klebsiella 
(2%). 
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PHYSIOLOGICAL ROLES OF EFFLUX: 
Role   in bacterial pathogenicity and virulence: 
 
In the efflux type, AcrAB-TolC - MDR phenotype of E. coli, helps in Pumping 
out  the bile salts which are toxic out of the cells. It helps the bacterium to get adapted   
to the animal GIT.  
 
Role   in bio film formation: 
 
   Any defect in efflux pump activity can impair the biofilm formation. Therefore, 
inhibition of any of the efflux activity by   inhibitors   can  reduce  biofilm  formation. 
In Streptomyces pristinaespirals the MFS family Ptr pump is an autoimmunity pump 
when it turns on the production of pristinamycins I and II. 
 
Neisseria, the MtrCDE system plays a significant role by providing   high 
resistance to faecal lipids in rectal isolates. 
  
In P. aeruginosa the MexXY component of the MexXY-OprM efflux is 
inducible by antibiotics which can target  ribosomes by PA5471 gene. 
92 
 
33 
 
 
METHODS TO DETECT EFFLUX: 
 
Several methods have been used to detect and quantify the activity of bacterial 
efflux pump systems using radio labeled, fluorescent or metal- labelled substrates to 
monitor the efflux in bacterial cell. Bulk measurement technique that use fluoresence 
spectroscopy yield a better and general understanding that represents the balance 
between entry and extrusion of a  substrate, which may result from efflux activity of 
one or several pumps and where cell membrane permeability also plays an important 
role.  
 
The development of a reliable and rapid method for detecting efflux pumps 
among the clinical isolates may positively assist for the selection of appropriate 
antibiotics in a given patient and also for the screening of resistance mechanisms in 
epidemiological surveys. There are various detection methods which can be classified 
into phenotypic and genotypic methods. The phenotypic methods are conventional 
and cost effective so that they can be used as first level screening to detect efflux. The 
available methods are: 
 
ETHIDIUM BROMIDE CARTWHEEL AGAR METHOD: 
 
It is an instrument free, simple, agar based method which uses Ethidium 
Bromide to demonstrate the activity of bacterial efflux. But the possibility of ruling 
out false positives in this screening method cannot be done as it has been studied that 
bacterial permeability to Ethidium bromide, may be decreased due to the porin down 
regulation.
10
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                                  Figure 5: An over view of cart wheel agar method 
 
 
  
INHIBITOR BASED ASSAYS: 
 
The presence of efflux is confirmed by the effect of efflux inhibitors on the 
MIC values of a particular antibiotic. Inhibitors like PAN, CCCP can be used in this 
assay. The effect of EPI on the resistance strains against the given antibiotic 
(imipenem) can be described as,  
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(i) Reversal – corresponds to no growth due to bacteria being fully susceptible to 
the antibiotic 
(ii) Reduction – corresponds to poor growth when compared to control, indicating 
that efflux is partially responsible 
(iii) No Effect- there is no change in growth, in the presence or absence of inhibitor 
thereby revealing that efflux has no role. 
 
CCCP SYNERGY TEST: 
 
Agar plates (muller hinton) are prepared which contains Carbonyl Cyanide 3-
Chloro phenylhydrazone (CCCP) at a concentration of about 12.5μM. The isolates are 
inoculated using a sterile cotton swab on to Carbonyl Cyanide 3-Chloro 
phenylhydrazone (CCCP) supplemented plate and simultaneously on to a plate which 
is devoid of CCCP.  Then a   meropenem   disc is placed on both the plates at the same 
time. The plates are incubated  at  37  degree  Celsius  for 18-24 hours. This test is 
considered positive when a synergy is observed between meropenem   and CCCP   on 
the CCCP-supplemented plate.
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GENOTYPIC METHODS: 
 
It is based on the principle of PCR which is the exponential amplification of a 
desired fragment of DNA, based on DNA replicative mechanism. It involves 
denaturation of the DNA which is double stranded, followed by annealing of primers 
for the desired amplicon and the extension of the primer. Different primers are 
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available to detect different genes involved in efflux. In our study the presence of 
mexE gene involved in imipenem resistant strains of Pseudomonas is studied.     
 
 VARIOUS STRATEGIES TO OVERCOME EFFLUX 
Biological inhibition: 
   This is done by blocking the protein and then using the antibodies or 
corresponding genes   to neutralize,   by any antisense approaches. 
 
Bypassing efflux pump: 
     The difference in transport can be seen within structural analogues of an antibiotic 
family.  
 
Pharmacological inhibitors: 
     The use of energy decouplers like, phenylalanine-arginine β-naphthylamide (PAN) 
and Carbonyl Cyanide 3-Chloro phenylhydrazone (CCCP) can be used to inhibit 
efflux. 
92
 
 
  
37 
 
 
This  prospective  study which was conducted in the Department of 
Microbiology, PSGIMS&R  after obtaining Institutional Human Ethical Committee’s 
(IHEC) approval. 
 
STUDY PERIOD: Jan 2015- July 2016 
SAMPLE SIZE: 50 
INCLUSION CRITERIA: 
Multidrug and pan drug resistant isolates of Pseudomonas aeruginosa (from 
any clinical sample) were included in the study. 
 
EXCLUSION CRITERIA: 
All susceptible strains of Pseudomonas aeruginosa were excluded. 
 
ETHICAL CLEARANCE: 
This prospective study was approved by the Ethical Committee of PSG 
IMS&R. It was renewed during the period of the study. 
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Pseudomonas aeruginosa from various samples like urine, pus, respiratory and 
wound swab were collected. Patient details of the collected samples were recorded. 
Gram staining was performed to check the morphology, biochemical tests were 
performed to further characterize the isolates of Pseudomonas aeruginosa according 
to  Schenkenberger classification,
14
 using the characteristic pigment production on 
nutrient agar, oxidase production, characteristic odor, growth at 42 degrees, nitrate 
reduction, gelatin hydrolysis, indole production, methyl red, voges proskauer, citrate 
utilization, TSI, Carbohydrate  fermentation. 
 
Following this antibiotic sensitivity was performed using disc diffusion method 
and simultaneously compared with the sensitivity obtained by VITEK 2 (BioMeriux, 
France). The zone diameters in disc diffusion were compared with that of CLSI for 
confirmation of sensitive and resistant isolates. On further testing, only those isolates 
which were resistant to carbapenems were   taken   to look for the activity of efflux.
 
 
ANTIBIOTIC SENSITIVITY TEST (disc diffusion):  
 
The Mid Log culture was prepared by inoculating the test organism in sterile 
nutrient broth and inoculating it in a shaker at 37
0
C for 4-6 hrs. Proper adjustments to 
the turbidity of the inoculums were made using McFarland’s tube 1, to make sure that 
the resulting lawn of growth is confluent. Sterile Muller Hinton Agar plates and swabs 
were prepared.  
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The plates were then inoculated by dipping the sterile swab into the mid log 
culture and swabbing all around the plate under sterile condition. Then five antibiotic 
discs were placed at an equal distance from each other and were slightly pressed down 
gently to have an even contact with the surface of the medium. These   agar plates 
kept for overnight incubation at 35
0
C. After incubation overnight, the diameter of each 
zones were measured and recorded in millimeter. These results were further 
interpreted according to the critical diameters by comparing with the standard table as 
in CLSI. 
 
ANTIBIOTIC SUSCEPTIBILITY BY VITEK 2: 
 
Automated systems like VITEK2 COMPACT (bioMérieux), are used for the 
evaluation of antibiotic susceptibility testing. Reliability of these automated systems 
when compared with reference method like agar dilution or microbroth dilution it 
holds good for determining susceptibility.    In VITEK 2 automated systems the 
procedure is done according to manufacturers instructions, the bacterial isolates 
should be freshly isolated, it should be single type of organism, freshly subcultured, 
matched with MC farland, (Gram-negative) GN271 VITEK 2 antibiotic susceptibility 
testing cards  are used.  
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ETHIDIUM BROMIDE CARTWHEEL AGAR METHOD: 
 
It is an instrument free, simple, agar based method which uses Ethidium 
Bromide to demonstrate the activity of bacterial efflux. It can simultaneously be done 
to 12 bacterial isolates, to detect those which have an over expression of efflux. All   
these plates should have one reference strain which will serve as a negative control for 
analysing fluorescence. 
 
This method used here is simple and it employs to prepare two sets of 
Trypticase soy agar plate which contains Ethidium Bromide at varying concentrations 
from 0.0 to 2.5 mg/L. These Trypticase soy agar plates were prepared on a fresh on 
the previous day of   experiment and it has to be kept protected from exposure to light.  
The bacterial cultures of overnight incubation of the isolates can be tested were 
prepared in a liquid media (Nutrient broth) their concentrations where kept to a   0.5 
McFarland standard.  The Trypticase Soy Agar plates were then divided into many 
sectors (with a maximum of twelve) by radial lines, thereby, forming a cartwheel 
pattern.  Bacterial cultures were swabbed onto the Ethidium Bromide -TSA plates 
starting right from the centre of the plate running towards the margin. The plates were 
incubated for 16 to 18 hours at 37 degree celsius.  After this period of time, the agar 
plates were examined in a gel imaging system.  The minimum concentration of 
Ethidium bromide which produces fluorescence in the bacteria were recorded and agar   
plates were   photographed. The temperature effect on these plates can be noted by 
placing them at different temperatures for incubation. 
1
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Confirmation of efflux system was done by checking Minimum Inhibitory 
Concentration by broth dilution method (MIC) 
 Preparation of stock solution: 
DRUG WEIGHT=C X V/P 
C=Capacity,V=Volume of water ,P=Potency of drug 
      Stock of drug (imipenem) was prepared according to the formula. 
10mg of drug was taken in the vial and mixed with 1ml of distilled water. 
 
 DRUG DILUTION: 
Drug was diluted in different ratio that is 1:32, 1:16, 1:8, 1:4, 1:2, 1:1, 1:0.5 
and   1: 0.25. The first tube had 2ml and other tubes have 1ml of single strength broth. 
Single strength broth of 105 micro litre was removed from the first tube. Instead 105 
micro litre of stock drug was added in place of that. Serial dilution was done, and 1ml 
was discarded from the last tube. 
 
 INNOCULUM PREPARATION: 
In 4ml of peptone broth or saline a loop full of   inoculum was added. They 
were incubated at   37
0
C for 3 to 4 hours. After incubation they were matched with 0.5 
McFarland`s standard (turbidity). 
 
 INHIBITOR PREPARATION: 
To 5ml of double strength broth, 200 microlitre of PaβN (Phenylalanine 
arginine  beta  naphthylamide) was added and mixed well. In a sterile micro titre plate 
the above mixture was added with the help of sterile micropipette. After the final 
preparation the following   procedure was followed: 100microlitre of double strength 
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broth was added to 50microlitre of drug dilution (0.25) inhibitor, PaβN  and  
50microlitre of inoculum. 
 
After adding to the micro titre well, it was allowed to settle well and further 
incubated for 16 hours at 37
 
degree celsius. Two controls were added. 
 
CONTROL1 consists of the double strength broth drug/inhibitor. 
CONTROL2 consists of   double strength broth and inoculum.    
 
The plates were incubated at 37
0
C for 16 hours and the MIC was recorded as 
the   lowest   concentration of the drug at which there was no growth at al. 
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CCCP synergy test:  
Agar plates (muller hinton) were prepared which contains Carbonyl Cyanide 3-
Chloro phenylhydrazone (CCCP) at a concentration of about 12.5μM. The isolates to 
be tested were prepared in a liquid media (Nutrient broth)   their concentrations were 
matched to a standard of   0.5 McFarland. 
 
The isolates were further inoculated using a a sterile cotton swab on to 
Carbonyl Cyanide 3-Chloro phenylhydrazone (CCCP) supplemented plate and 
simultaneously on to a plate which is devoid of CCCP.  A maximum of 2 isolates can 
be inoculated on a single plate plate. Then place a meropenem   disc on both the plates 
at the same time for each set of inoculation. The above plates are incubated at 37 
degree Celsius for 18-24 hours. This test is considered positive when a synergy is 
observed between meropenem   and CCCP   on the CCCP-supplemented plate. 
91
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POLYMERASE CHAIN REACTION: 
Preparation of isolates: 
 
The isolates from which DNA where extracted was first inoculated in Luria – 
Bertani medium (broth) which contained for 1000 ml of distilled water, 5 gms of 
sodium chloride, 5 grams of yeast extract and 10 grams of trypton. The broth was 
incubated overnight and two to three ml was used for extraction.  Extraction was done 
using boiling method. 
 
Principle of PCR: 
 
PCR is based on the principle of exponential amplification of a desired 
fragment of DNA, based on DNA replicative mechanism. It involves denaturation of 
the DNA which is double stranded, followed by annealing of primers for the desired 
amplicon and the extension of the primer. 
96
 
 
Instruments and materials: 
 
Vortex mixer 
Refrigerated micro centrifuge –Legend Micro 21R 
Thermo cycler 
Dry bath - Thermocon DB900 
Micropipettes 1000 μl, 100 μl and 200 μl 
Barrier tips 1000 μl and 200 μl  
                 
45 
 
 
Figure 6: Materials required for PCR 
 
 
 
 
DNA EXTRACTION PROCEDURE 
 
About 2 ml aliquots of the test organism were grown in LB broth and was 
centrifuged at 5000 revolutions per minute (RPM) for 10 minutes. Pellets were re- 
suspended in 100 µl of sterile distilled water. The suspension was kept  in a water bath 
at 95°C for 20 minutes. It was then cooled and centrifuged at 5000 RPM for 10 
minutes. The supernatant was used for PCR, and the extracted  DNA was stored at  - 
20°C. 
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PCR for detecting   mexE gene: 
 
PCR was carried out on the sixteen isolates which were phenotypically 
confirmed to be resistant to carbapenems due to an increase in activity of efflux 
system.  
 
The primers used were obtained from Sigma Aldrich, Mumbai, which were 
based on the reference articles from a previous study.  The detection of mexE was 
done using  5’GTCATCGAACAACCGCTG 3’ as forward primer and 
5’GTCGAAGTAGGCGTAGACC3’ as the reverse primer which eventually produces 
an amplicon size of 516 bp. 
96 
mexE being the gene to detect the efflux system 
MexEF-OprN where mexE is the gene responsible for efflux and F is the membrane 
usion protein and OprN is the outer membrane protein. Thorough detection of the 
whole system can be done by SDS PAGE. 
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Reaction mixture: 
Each single reaction mixture (25μl) contained 4 μl of DNA suspension, 12.5 μL 
of Master Mix (10mM dNTPs, 1 U Taq DNA polymerase, 25mM MgCl2 and 2.5 μl of 
10 x Taq buffer ) and 1μM of each primer (Sigma- Aldrich, Mumbai). The remaining 
volume was adjusted with PCR grade water. 
Positive and negative controls were setup with each batch of tests run. 
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Polymerase chain reaction: 
The PCR was performed by conventional method using a Eppendorf thermal-
cycler, under the following conditions. 
 
Initial denaturation at 95°C for 2 minutes, 32 cycles of 95°C for 25 seconds, 
annealing temperature 60°C for 45 seconds and extension at 72°C for 1 minute and a 
final elongation at 72°C for 3 minutes. The products after amplification are stored at -
20°C until they were subjected to agarose gel electrophoresis. 
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Agarose gel electrophoresis: 
The amplified product is visualized by use of agarose gel electrophoresis. The 
agarose gel was prepared to a ratio of 1% by adding agarose gel powder with Tris 
Borate EDTA (TBE) buffer. This mixture was heated in microwave till it becomes a 
clear solution and followed by the addition of Ethidium bromide was added to 
visualize the amplified DNA under UV light. The mixture was allowed to set in an 
electrophoresis tank with comb in place.  
 
A 100 base pair ladder was used as the molecular marker to measure the size of 
the amplified product from the PCR in the first well and the rest of the wells had 5μl 
of the amplified product along with 3 μl of the loading dye from Sigma Aldrich was 
used to visually see the movement of the product. The gel electrophoresis was 
performed by placing the gel in an electrophoresis tank containing Tris Borate EDTA 
(TBE) buffer at 100 volts for 40 minutes. 
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Interpretation: 
 
The ethidium bromide was used to stain the amplified DNA for visualization 
under UV illumination. Then images of the gel were captured by Gel doc. The 
presence of the amplified DNA fragments of the mexE gene is confirmed by the 
formation of bands corresponding to their molecular weight and a 100bp ladder that 
was used for this purpose. The sixteen which were phenotypically proven were found 
to be positive for mexE  gene having 516bp. 
95
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A total of 50 clinical isolates of Pseudomonas aeruginosa   from different 
clinical samples like pus, urine, respiratory specimens were  taken  and  characterized 
by biochemical tests and antibiotic susceptibility was performed by Kirby bauer 
method.  Strains   which were carbapenems resistant were taken into study.  Of the 
multi drug resistant strains 17% were carbapenem resistant.  
 
Characterisation of Pseudomonas aeruginosa was based on the gram stain 
morphologyshowing gram negative rods (fig.7), pigment production on nutrient 
agar(fig. 8),  a positive oxidase test(fig. 9) , and  biochemical characters  as shown in 
figure 11.   
 
Figure 7:  GRAM STAIN MORPHOLOGY 
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Figure 8: Pseudomonas aeruginosa ON   NUTRIENT AGAR 
 
 
 
          
 
 
 
Figure 9:  OXIDASE TEST (+) 
 
 
 
 
               
 
 
Figure 10: antibiotic sensitivity test  on  muller hinton agar: 
 
 
 
 
 
Resistant to ceftizidime, cefotoxime, imipenam, meropenam, amikacin and 
ciprofloxacin. 
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Figure 11: biochemical reactions of Pseudomonas aeruginosa: 
 
 
 
From left to right: 
1. Indole - Negative  5. Sucrose - Negative 
2. Urease - Negative  6. Mannitol - Negative 
3. Glucose - Acid (Oxidative)  7. Urease - Negative 
4. Lactose - Negative  8. TSI - K/K -,- 
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DISTRIBUTION OF ISOLATES AMONG CLINICAL SAMPLES 
 
 Clinical isolates of Pseudomonas were collected from various samples with 
a maximum contribution from pus and wound swabs followed by respiratory samples 
as shown in the figure 12 below. 
 
Fig 12:  Distribution of isolate among clinical samples 
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RESISTANCE RATES OBSERVED AMONG VARIOUS ANTIBIOTICS IN 
Pseudomonas aeruginosa 
 
           The resistance rates observed among different antibiotics in clinical isolates of 
Pseudomonas aeruginosa are shown in figure 13 with a maximum rate for beta 
lactams followed by quinolones and the minimum for carbapenems. 
 
Fig 13:   Resistance rates among various antibiotics 
 
 
 
 
 
54 
 
 
TABLE 4: RESISTANCE PATTERN OF Pseudomonas aeruginosa TO 
VARIOUS ANTIBIOTICS 
 
                   ANTIBIOTICS              RESISTANCE RATE (%) 
Piperacillin 29 
Ceftazidime 31 
Gentamicin 31 
Amikacin 32 
Ciprofloxacin 40 
Piperacillin tazobactum 35 
Cefepime 30 
Imipenem 17 
Meropenem 16 
Tobramycin 29 
Levofloxacin 42 
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MECHANISM OF CARBAPENEM RESISTANCE 
 
Out of the 50 isolates nearly 32% had efflux as a mechanism for carbapenem 
resistance while the rest were due to metallo beta lactam production, impermeability, 
outer membrane protein defect or loss of porins. 
 
Fig 14:    Mechanism of carbapenem resistance 
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PREVALANCE OF EFFLUX IN THE ISOLATES 
   
 Efflux mediated drug resistance was detected in 32% of the clinical isolates 
of Pseudomonas aeruginosa. 
 
Fig 15:   Prevalence of efflux in the isolates 
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PHENOTYPIC METHODS FOR DETECTING EFFLUX MEDIATED 
RESISTANCE 
 
Ethidium bromide cart wheel agar, inhibitor based assays like MIC detection 
using inhibitors and CCCP synergy test detected efflux mediated resistance in 20 and 
16 isolates respectively. 
 
Fig 16: Phenotypic detection of efflux mediated resistance 
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DETECTION OF EFFLUX MECHANISM BY ETHIDIUM BROMIDE AGAR 
CARTWHEEL METHOD 
 
The EB-agar cartwheel method used for the presumptive identification of over 
expression of  efflux systems showed efflux activity in 20 strains.     
Figure 17: Et-Br cart wheel agar showing fluorosence at different concentrations. 
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Fig 18: Absence of efflux activity: 
 
 
 
0.0mg/L  0.5mg/L 
 
 
 
1.0mg/L  1.5mg/L 
 
 
 
2.0mg/L  2.5mg/L 
 
 
       
60 
 
 
DETERMINATION OF EFFLUX ACTIVITY AT VARIOUS 
CONCENTRATIONS OF ETHIDIUM BROMIDE 
 
Clinical isolates without efflux pump activity were found to fluoresce at 0.5 
mg/l concentration of EB as observed in the ATCC strains taken as negative controls. 
The minimum concentration of EB at which strains with efflux activity showed 
fluorescence was 1mg/l. At this concentration efflux activity was observed in 20 
isolates.     
Table 5: Determination of efflux activity at various concentrations of ethidium 
bromide 
No. of isolates  
(p.aeruginosa) 
Concentration of Et-Br at 
which bacteria  did not  
fluoresce (mg/l) 
 
Efflux activity 
 
30 < 0.5 - 
9 1.0 + 
7 1.5 ++ 
4 2.5 +++ 
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TABLE 6: COMPARISON OF   ETHIDIUM BROMIDE CART WHEEL 
AGAR   METHOD WITH PCR FOR DETECTION OF EFFLUX 
 
CART WHEEL 
AGAR 
PCR Total 
Positive Negative 
Positive 16 4 20 
Negative 0 30 30 
Total 16 34 50 
 
SPECIFICITY OF Et- Br   = 30/34 * 100 =   88.2% 
SENSITIVITY OF Et- Br  = 16/16 * 100=   100% 
POSITIVE PREDICTIVE VALUE = 16/20 * 100 = 80% 
NEGATIVE PREDICTIVE VALUE = 30/30 * 100 = 100% 
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THE EFFECT ON MICs IN CLINICAL ISOLATES BY EFFLUX 
INHIBITORS USING INHIBITOR BASED ASSAYS 
                
   Out of the 50 isolates, nearly 16 isolates had a reduction in MICs making it 
sensitive to the antibiotic. The isolates which showed a four-fold decrease where 
considered as REVERSAL and those with two fold were considered as REDUCTION. 
 
Based on the above results, almost 7 isolates had four fold  decrease in MIC 
and 9 of them had two to one fold decrease in MIC values and the rest had no change 
at all.  
 
Table 7: Strains of Pseudomonas aeruginosa used in this study and   comparision 
of their MICs(µg/mL) for imipenem, tested in the absence / presence of  PAN (50  
µg/mL) 
 
Bacterial 
Strains 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Imipenem 4 8 32 4 8 8 16 4 8 32 16 16 32 32 4 8 
Imipenem 
+ PAN 
1 1 2 1 2 1 2 1 2 2 1 2 2 2 1 2 
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Table 8: Effect on the MICs after using inhibitors 
 
 
No of isolates 
MIC before 
adding inhibitor 
MIC after 
adding inhibitor 
Interpretation 
7  16 < 2 REVERSAL 
9  8 < 2 REDUCTION 
34  8  8 NO EFFECT 
 
Figure 19:  Efflux confirmation by MIC with Imipenem with and without PAN 
by micro titre plate method. 
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CCCP TEST 
The test is considered positive when synergy between meropenem and CCCP is 
observed on the CCCP-supplemented plate.  Synergy was exhibited by 16 isolates.                                        
             
                   Figure 20: showing synergy between CCCP and meropenem 
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 GENOTYPIC DETECTION – PCR 
The isolates were tested for the presence of mexE gene using  the  respective 
primers. All the 20 isolates which tested positive by phenotypic methods (Et- Br and 
inhibitor based assays) were subjected to PCR for confirmation and molecular 
characterization. Out of these 16 isolates showed the presence of mexE gene.       
                             
Figure 21:   Gel Electrophoresis picture showing mexE gene. 
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COMPARISON OF VARIOUS METHODS FOR THE DETECTION OF 
EFFLUX 
 
The phenotypic methods used for detection of efflux like, cart wheel agar and 
inhibitor based assays detected efflux in 20 and 16 isolates respectively. Those proven 
to exhibit efflux by phenotypic methods were confirmed by genotypic method which 
is the PCR. 
 
Fig 23:  Comparison of various methods for the detection of efflux 
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Pseudomonas aeruginosa is one of the important and leading cause of life 
threatening nosocomial infections like, ventilator associated pneumonia (VAP), burns 
wound infections, septicemia in neutropenic patients and disseminated infections. A 
combination therapy which consists of two anti pseudomonal drugs like, a beta-lactam 
antibiotic with an aminoglycoside is usually prescribed for the initial empiric 
treatment. Infections caused by Pseudomonas are becoming increasingly resistant to 
many of the antibiotics, and it may also acquire resistance during therapy. Resistance 
is established due to a single factor or a combination of several mechanisms like, 
alteration of the target, inactivation of the drug, over activity of efflux
. 
Pseudomonas 
produces a variety of beta lactamases like extended spectrum beta lactamases (ESBL), 
chromosomal cephalosporinase (AmpC) and metallo beta lactamases (MBL).                         
Inherent resistance to many antibiotics along with other acquired mechanisms makes 
it more problematic in the antibiotic era.  
 
In a study conducted by Jayakumar et al. in our own centre, reported 22% of 
the clinical isolates of Pseudomonas as multi drug resistant and 4% as  pan drug 
resistant.  ESBL and MBL producers were found to be 15.5% and 54.5% 
respectively.
62
 Studies conducted by Senthamarai et.al., in India showed Pseudomonas 
isolates with higher prevalence of Multi Drug Resistance (41.35%) and ESBL 
producers (42.3%) and a  lower (15.38 %) prevalence of  MBL producers.  
96
 Agarwal 
et al., showed a prevalence of 22.22% being ESBL producers  and  20.27% producing 
MBL. 
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The resistance rates observed in our study among the clinical isolates of 
Pseudomonas was as follows: Ceftazidime (31%), Piperacillin (29%), ciprofloxacin 
(40%), levofloxacin (42%), cefepime (30%) carbapenems (17%) which is less when 
compared with other centers in India. 
96
 
 
Carbapenems like Meropenem, imipenem and doripenem are the drugs of 
choice in treating multi drug resistant Pseudomonas in health care settings.   They are 
proven effective against beta lactam producing strains.  Increase in prevalence of 
carbapenems resistance is observed worldwide.
63
 a study in UK showed that 
prevalence of carbapenem resistance over the past five years in a tertiary care hospital 
showed a rise in trend from 53% to 88%. In addition mutations in OprD can inhibit 
the entry of imipenem into the bacterial cell
64-66.
  
 
At present, 17% of the clinical isolates of P.aeruginosa were resistant to 
carbapenems (unpublished data). Lot of studies have been done on carbapenems 
resistance in India and other countries particularly about the over expression of MBL 
and AmpC cephalosporinase. However, in India, very few studies have investigated 
efflux pumps as a mechanism of carbapenem resistance in Pseudomonas. 
 
Active efflux in bacteria is one effective mechanism which is responsible for 
moving compounds such as antibiotics, neuro transmitters and toxic products out of 
the bacterial cell. It is of prime importance in the xenobiotic metabolism. Efflux is 
known to play a key role in the development of antimicrobial resistance in 
Pseudomonas.
11
 The efflux  allows the bacterium to regulate the environment inside 
by excreting substances which are harmful like, antibiotics, quorum-sensing 
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molecules and toxic metabolites. These pumps are classified into five: major 
facilitator super family (MFS), adenosine triphosphate (ATP)-binding cassette super 
family, the resistance-nodulation-cell division (RND)  family, small multi drug 
resistance family (SMR) and the multidrug and toxic compound extrusion (MTE) 
family
4-6
. Drug resistance observed in medically important bacteria like Pseudomonas 
are predominantly of the RND type. It allows for acquisition of resistance to various 
antibiotics which are available. 
 
Among the various efflux pumps in RND, the Mex family is what 
predominates in the Pseudomonas. MexAB- OprM and MexXY-OprM are found to be 
associated with both acquired and intrinsic resistance, whereas MexEF-OprN and 
MexCD-OprJ are attributable to acquired resistance alone. 
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Several methods have been used to detect and quantify the activity of bacterial 
efflux pump systems using phenotypic and genotypic methods. Phenotypic methods 
include, a radio labeled, fluorescent or metal- labeled substrates to monitor the efflux 
in bacterial cell. Bulk measurement techniques that use fluorescence spectroscopy 
yield a better and general understanding of efflux. It expresses the balance between 
entry and extrusion of a substrate, which may result from efflux activity of one or 
several pumps. However, these methods are expensive, technically demanding and 
also require special equipments.  
 
The phenotypic methods which are conventional and cost effective are required 
for screening of efflux in bacteria. The development of a reliable and rapid method for 
detecting efflux pumps among the clinical isolates like, Ethidium bromide cart wheel 
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agar and inhibitor based assays may positively assist for the selection of appropriate 
antibiotics in a given patient and also for the screening of resistance mechanisms in 
epidemiological surveys.  
 
Recently a semi automated fluorometric method which has been developed for 
the detection of efflux pump activity in bacteria. This method uses a common efflux 
pump substrate Ethidium Bromide (EtBr) which has been shown to be particularly 
suitable for these studies. Ethidium bromide –agar method is a Simple, instrument-
free, agar-based method that utilizes Et-Br for the demonstration of efflux pump 
activity in bacteria. 
93
 
 
In our study, the prevalence of efflux mediated drug resistance in clinical 
isolates of Pseudomonas using cart wheel agar method was found to be 40%(n=20). 
Similar observations were made by Manju suresh et al., from Kerala and Choudhry et 
al., from North India. 
85
 
 
The principle of this fluorometric assays is the passage of EtBr across the 
cytoplasmic membrane and its subsequent intracellular accumulation inside the 
bacterial cell 
8
. EtBr traverses the bacterial cell wall (in the case of Gram-negative 
bacteria via porin channels) and once inside, it can be concentrated to a point where it 
fluoresces when excited by ultraviolet (U.V.) light. Efflux pumps of MDR bacteria 
recognize this substrate and are able to extrude it to the medium
6, 8
.  
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These efflux systems are temperature dependent and this process will continue 
if the concentration of EtBr in the culture medium does not overcome the capacity of 
the bacterial efflux pump itself. Therefore, loading of the bacteria with Et-Br has to 
take place at a concentration that is well below its minimum inhibitory concentration 
(MIC) 
4,5
.        
            
Clinical isolates without efflux pump activity were found to fluoresce at 0.5 
mg/l concentration of EB as observed in the ATCC strains taken as negative controls. 
The minimum concentration of EB at which strains with efflux activity showed no 
fluorescence was 1mg/l. At this concentration efflux activity was observed in 20 
isolates out of the 50 studied. 
 
The strains expressing increased levels of efflux activity by the EtBr-agar 
cartwheel method were selected for further characterization. The conformational 
studies aimed to determine the MIC by broth micro dilution for an antibiotic 
(imipenem) in the presence and absence of EPI (PAN), thereby confirming or 
excluding the presence of increased efflux activity and its contribution to the MDR 
phenotype.  
 
There are many efflux inhibitors like, phenylalanine-arginine β-naphthylamide 
(PAN), Carbonyl Cyanide 3-Chloro phenylhydrazone (CCCP) and reserpine but none 
of them are available for clinical use. While CCCP and PAN can be used in gram 
negative bacilli, reserpine is used exclusively on gram positive bacteria.  
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Hence, all the isolates were subjected to an efflux pump inhibitor 
phenylalanine-arginine β-naphthylamide (PAN) based confirmatory method which 
showed reduction in the MICs for 16 isolates. Further, the effect of EPI on the 
resistance strains against the given antibiotic (imipenem) was done as described by 
Martin et.al 2010 
10
 as, Reversal – corresponds to no growth due to bacteria being 
fully susceptible to the antibiotic. Reduction – corresponds to poor growth when 
compared to control, indicating that efflux is partially responsible. No effect- there is 
no change in growth, in the presence or absence of inhibitor thereby revealing that 
efflux has no role.      
 
According to this classification, the MICs measured in the presence and 
absence of PAN for the given antibiotic (imipenem) was tested using broth dilution 
technique. Based on the results, 45% of the isolates(7) had a four-fold decrease 
(reversal) in MIC bringing it down to < 2 in the presence of PAN, making it highly 
probable for the presence of an efflux. Nearly 35% of the isolates had a two to one 
fold decrease (reduction) in MIC in the presence of PAN, thus making it probable for 
efflux in those isolates. The remaining 20% of the isolates had no change in the MIC 
values thus ruling out efflux as a mechanism of resistance. 
 
The effect of another inhibitor namely, Carbonyl Cyanide 3-Chloro 
phenylhydrazone (CCCP) was demonstrated simultaneously by demonstrating the 
synergy between the antibiotic used (meropenem) and the inhibitor. The test was 
considered positive when synergy between meropenem and CCCP was observed on 
the CCCP-supplemented plate.  The 16 isolates which showed reduction in MICs as 
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mentioned above, were exhibiting synergy with this inhibitor as well. This test is cost 
effective and not time consuming. It has a specificity of 100% and can be employed as 
a routine test to detect efflux. 
91
 
 
In comparison to the conformational studies like the inhibitor based assays, the 
ethidium bromide cart wheel agar has a specificity and sensitivity of 89% and 100% 
respectively. The positive predictive value and negative predictive value are 80% and 
100% respectively thereby, making it suitable as a first line screening test. But the 
possibility of ruling out false positives in this screening method cannot be done as it 
has been studied that bacterial permeability to Ethidium bromide, may be decreased 
due to the porin down regulation. 
10
 
 
Molecular methods are emerging as one of the most important tools in 
detection of drug resistance in various organisms including efflux mechanisms. In 
Pseudomonas the mex family belonging to RND plays a prominent role in resistance 
to various antibiotics.  While mexAB OprM is associated with resistance to 
penicillins, cephalosporins, carbapenems, monobactams and fluoroquinolones.  
 
This pump has a broad substrate specificity and detecting this gene mexA will 
require further quantification which is time consuming. MexCD OprJ is related to 
monobactams, quinolones, few penicillins and cephalosporins. MexXY OprM can 
lead to resistance of fluoroquinolones and aminoglycosides. (table 2)
82
. However 
mexEF OprN is related to carbapenems and quinolones resistance.  
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All the isolates which tested positive for efflux in our study must belong to 
mexEF-OprN as we have used imipenem with and without PAN to confirm efflux in 
P.aeruginosa. So detection of mexE gene indicates that carbapenems resistance in 
Pseudomonas isolates is due to the over expression of mexEF OprN pump.
5
 The mexE 
gene codes for periplasmic fusion protein, mexF is a cytoplasmic membrane efflux 
pump and oprN is the outer membrane protein. Amplification of mexE was performed 
using 5’GTCATCGAACAACCGCTG3’ as forward primer and 
5’GTCGAAGTAGGCGTAGACC3’ as the reverse primer, on all isolates which tested 
positive for efflux by inhibitor based assays. Strains over expressing this gene have an 
increased resistance to imipenem and quinolones. The 16 isolates which were positive 
by the inhibitor based methods were found to express mexE gene thereby confirming 
the presence of an efflux   mediated resistance in these isolates. Molecular 
characterization of these pumps have been done by kohler et.al., 
95 
Molecular 
characterization of this MexEF-OprN efflux system has not been done from this part 
of the world yet. 
 
PCR was not done on all isolates, because, mexE stands as a marker for drugs 
like quinolones other than carbapenems (Table 2). Since, only carbapenem resistant 
isolates were taken in our study we did PCR to confirm the presence of efflux MexEF 
oprN.                
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Since, there is a narrow substrate specificity of mexEF oprN and imipenem 
being one of the substrate, the increase in usage of imipenem may lead to selection of 
efflux mediated mutants, with higher MICs which demands for awareness, control and 
proper therapeutic option.   
 
There are many studies going on in search of an effective efflux inhibitor, that 
can be used therapeutically to treat infections in MDR bacteria which are efflux 
mediated. Few of the natural derivative products have shown to exhibit anti-efflux 
pump activity including the carotenoids capsorubin and capsanthin, the alkaloid 
lyserogol and flavonoids chrysin and rotenone.
91
 Efflux inhibition studies using   plant 
extracts like rutin, kaemferol, catechin, coumaricacid , caffeic acid, chlorogenic acid 
and quercetin  was carried out in our centre  on isolates of Pseudomonas aeruginosa, 
showed reduction in MICs (unpublished data).  
 
This aspect of EPI assumes more clinical significance, because, this can 
literally revert bacterial resistance to the available antibiotics. It can be used along 
with antibiotics for therapeutic purposes.  
 
Efflux is one of the novel mechanisms which bacteria use to defend themselves 
from antibiotics and thereby establishing resistance. So there is a need for 
development of a reliable and rapid method for detecting efflux pumps among the 
clinical isolates which assist for the selection of appropriate antibiotics for a given 
patient. Equally important is to find a safe and reliable inhibitor of efflux, which can 
be used along with antibiotics on patients.  
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 A total of 50 multi-drug resistant isolates of Pseudomonas aeruginosa were 
selected for the detection of efflux mediated drug resistance. 
 Their identity was further characterized by both phenotypic and VITEK 
automated identification method. 
 Multi drug resistant isolates were taken and antibiotic susceptibility testing was 
done by Kirby bauer disc diffusion and compared with VITEK2 automated 
system. 
 All the 50 isolates were screened for efflux mediated drug resistance by 
ethidium bromide cart wheel agar method. 
 In Ethidium bromide cart wheel agar method 20 isolates (40%) tested positive 
for efflux activity. 
 Further confirmation of this efflux activity was done by efflux  inhibitor  based 
assays where MIC detection was done by micro broth technique using 
phenylalanine-arginine β-naphthylamide (PAN). 
 This test confirmed the presence of efflux in 32% (n=16) of  the isolates.  
 Simultaneously, synergy test using another inhibitor, Carbonyl Cyanide 3-
Chloro phenylhydrazone (CCCP) was done on all isolates. Synergy was 
exhibited by 32% of the isolates (n=16). 
 Molecular characterizationof the efflux positive isolates were done to detect 
mexE gene by PCR.  
 All the 16 isolates which were positive for the presence of efflux were detected 
with the presence of  mexE gene.  
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 Efflux activity was observed in 32% (n=16) of the isolates. 
 Ethidium bromide cart wheel agar and efflux inhibitor based assays were 
compared with PCR as the gold standard method. 
 Ethidium bromide cart wheel agar has a specificity and sensitivity of 89% and 
100% respectively. The positive predictive value and negative predictive value 
are 80% and 100% respectively thereby, making it suitable as a first line 
screening test. 
 The inhibitor based assays had a specificity of 100% and can be used as 
confirmatory methods to detect efflux 
 
 
                 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
       Pseudomonas aeruginosa is one of the important nosocomial pathogen with 
increase in incidence of carbapenem resistance. Routine antibiotic susceptibility tests 
fail to recognize efflux mediated resistance. Thus, the phenotypic or genotypic 
detection methods must be done in clinical isolates. This study reports on the emergence 
of efflux pump-based multidrug-resistance in   Pseudomonas aeruginosa. Our results showed 
that 32% of drug resistance in MDR strains of P.aeruginosa is attributable to efflux-related 
mechanisms, thereby emphasizing the need for inclusion of efflux-related tests in the 
diagnostic regimen for MDR clinical bacteria, to facilitate implementation of appropriate 
therapy to the ailing patients. The role of efflux inhibitors is to be taken into account 
for therapeutic options. 
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